The supply situation and purchase method of Quizartinib in the Hong Kong market

Quizartinib is an oral small molecule kinase inhibitor that targets FLT3 mutations. It is mainly used to treat FLT3-ITD mutation-positive relapsed or refractory acute myeloid leukemia (AML) patients. Although the drug has been approved for marketing in some European and American countries, it has not yet been officially approved in mainland China. Therefore, if domestic patients have drug needs, they need to purchase drugs through overseas channels. As a region with relatively open medical resources, Hong Kong has become an important window for many mainland patients to obtain new anti-cancer drugs.

In Hong Kong, the original version of Quizartinib has not yet been widely introduced into the public hospital system, but some large private hospitals or authorized pharmacies are expected to provide this drug to eligible patients through the "Special Drug Application" form. However, since the drug is still in limited supply in Hong Kong, it usually requires a doctor's prescription or is purchased after evaluation by a specialist, and the process is relatively strict. Patients are advised to contact relevant medical institutions in Hong Kong in advance to find out whether there are drug supply channels and prepare relevant medical information.

In addition to original drugs, there are also more affordable generic versions on the market to choose from. In particular, the generic drugs produced by Luzhou Pharmaceuticals in Laos (Luzhou Pharmaceuticals) are relatively common and cost-effective. This version is divided into two specifications: 17.7 mg These generic drugs can usually be obtained through regular cross-border pharmacies or purchasing platforms in Hong Kong, but attention must be paid to the legality and quality assurance of the drug sources.

Generally speaking, the supply of quizartinib in the Hong Kong market is still mainly through overseas import channels, and the purchase method is mainly through private medical institutions, authorized pharmacies or cross-border pharmaceutical service platforms. When choosing, patients are advised to give priority to regular institutions recommended by doctors, and learn more about the version, price, and indications of the drug to ensure drug safety and therapeutic effect. For patients with limited budgets, generic versions of Lucius offer a more viable alternative, but should be used rationally under physician guidance.

Reference materials:https://www.drugs.com/